|
 |
 |
|
|
|
|||||
|
Overview Directors Codes of Conduct |
 Marshall Edwards, Inc., (the Company) is a subsidiary of the Australian pharmaceutical company, Novogen Limited. The Company was formed to commercialize an important recent discovery in the oncology field - a new family of chemicals known as multiple signal transduction regulators. This new family of anti-cancer drugs was discovered originally by Novogen scientists. The Comany was formed in order to provide a scientific and commercial focus for this new family of drugs. The Company is dedicated to developing a number of these new drug candidates to become a new generation of anti-cancer therapies, to be used across a broad range of cancer types. The first multiple signal transduction regulator drug, phenoxodiol, currently is in Phase III trials. A number of other multiple signal transduction regulator anti-cancer drugs are being developed. Marshall Edwards, Inc., is listed on the Nasdaq market in the United States of America (Code: MSHL). View investment information |
|
140 Wicks Road North Ryde NSW 2113 Australia T: +61 2 8877 6196  |
      
|
| . |
home
: about us.
: about phenoxodiol
: the technology
: newsroom
: Marshall Edwards Inc. 2001 ©
|